Interius BioTherapeutics

Interius BioTherapeutics has been acquired by Kite, a Gilead Company. Follow Kite Pharma for updates.

Interius BioTherapeutics, families, and friends enjoyed a grand time with the Philadelphia Phillies at the ballpark! We should be back next year! Go Phils!

Today, we announced that Interius BioTherapeutics has entered into a definitive agreement to be acquired by Kite Pharma, a Gilead company. This marks a pivotal moment in our journey. By combining Kite’s deep expertise in cell therapy with Interius’s talent and research, we’re unlocking a bold new chapter that will accelerate the development of in vivo therapies and expand access for patients facing aggressive or advanced disease around the world. Interius’s novel platform is designed to create therapeutic CAR cells directly in the patient’s body following a single intravenous infusion, expanding the opportunity for access to cell therapies and delivering meaningful innovation to patients. We’re incredibly proud of what we’ve accomplished to date and even more excited about what’s ahead. Learn more about this announcement: https://lnkd.in/eyvQ4NHT

Our very own Sianny Christanti and Babu Medi, B.Pharm, Ph.D make Interius BioTherapeutics shine on Tyler Menichiello's new podcast Better Biopharma discussing in vivo CAR-T development. Tune in to find out more!

Help Interius BioTherapeutics raise funds for the American Association for Cancer Research (AACR) during the Philadelphia Marathon Weekend in November 2025! Share this message, make a donation today, and come cheer on Team Interius! https://lnkd.in/eUNNGucA

We’re #hiring a new Research Assistant/Research Associate, Analytical Development in Philadelphia, Pennsylvania. Apply today or share this post with your network.

What a way to kick off the holiday week with Interius BioTherapeutics's first peer-reviewed paper being published! The development of CAR T cell therapies has greatly impacted the treatment of B cell malignancies; however, manufacturing these patient-specific, autologous cell therapies is complex, costly and requires preconditioning chemotherapy prior to infusion, limiting patient access. In the publication we describe the development of a lentiviral platform based on a novel, detargeted viral fusogen (Gen 2.1 Fusogen) and a membrane-bound targeting moiety to enable in vivo targeted delivery of stably integrating genetic medicines without the need for lymphodepletion. INT2104 employs an scFv targeting CD7 (“CD7 Binder”) to deliver a CAR20 transgene to CD7+ T and NK cells. Preclinical data generated in mouse and cynomolgus macaque models indicate INT2104 results in both CAR T cells (CD4+ and CD8+) and CAR NK cells with subsequent depletion of CD20+ B cells following a single intravenous administration. Thus, INT2104 could potentially provide a more accessible, off-the-shelf treatment option for patients who may benefit from CAR therapies. To read more, follow the link: https://lnkd.in/efbTVUdS #CART #cellandgenetherapy #cartherapy #biotech #phillybio #patientaccess

Interius BioTherapeutics President and CEO Philip R. Johnson, MD continued to share our story and meet with friends across the industry at the BIO International Convention this week. Thank you to the organizers for an exciting panel "In Vivo CARs: Unlocking the Potential of Immune Cell Programming in Oncology and Beyond". #BIO2025 #CART #cellandgenetherapy #cartherapy #biotech

Today is recognized as Clinical Trials Day. An initiative of the ACRP - Association of Clinical Research Professionals, this day urges us to recognize the researchers, principal investigators, clinical care teams, sponsors, clinical research coordinators, and countless others involved in bringing hope and the potential of new medicines to patients. Above all, let's take a moment to thank the families and selfless patients, who enable moving science and medicine forward for all of us. #ClinicalTrialsDay #CTD2025 #CART #cartherapy #cellandgenetherapy

We’re #hiring a new Lab Manager in Philadelphia, Pennsylvania. Apply today or share this post with your network.